Engineered protease-resistant antibodies with selectable cell-killing functions

Journal of Biological Chemistry

Volumn 288, Issue 43, 2013, Pages 30843-30854

  Kinder, Michelle ^a   Greenplate, Allison R ^a   Grugan, Katharine D ^a   Soring, Keri L ^a   Heeringa, Katharine A ^a   McCarthy, Stephen G ^a   Bannish, Gregory ^b   Perpetua, Meredith ^b   Lynch, Frank ^c   Jordan, Robert E ^a   Strohl, William R ^a   Brezski, Randall J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Huntingdon Life Sciences New Jersey   (United States)

^c QualTek Molecular Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY THERAPEUTICS; ANTIGEN BINDING; HOST IMMUNE RESPONSE; INVASIVE TUMORS; MICROBIAL PROTEASE; MICROENVIRONMENTS; PROTEOLYTIC CLEAVAGE; SPECIFIC CLEAVAGES;

CELLS; CYTOLOGY; ENZYME ACTIVITY; RESTORATION; SCAFFOLDS (BIOLOGY); TUMORS;

ANTIBODIES;

FC RECEPTOR; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; PROTEINASE;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CELL KILLING; CHO CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; MACACA FASCICULARIS; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SQUAMOUS CELL CARCINOMA;

ANTIBODY ENGINEERING; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGES; NK CELLS;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING SITES, ANTIBODY; CELL LINE; HUMANS; IMMUNOGLOBULIN G; PROTEIN ENGINEERING; PROTEOLYSIS; RECEPTORS, IGG;

EID: 84886699076     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.486142     Document Type: Article

References (80)

1. Presta, L. G. (2008) Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20, 460-470
2. Strohl, W. R. (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr. Opin. Biotechnol. 20, 685-691
3. Reichert, J. M. (2010) Metrics for antibody therapeutics development. MAbs 2, 695-700
4. Weiner, L. M., Surana, R., and Wang, S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317-327
5. Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., and Mulkerrin, M. G. (2001) Engineered antibodies with increased activity to recruit complement. J. Immunol. 166, 2571-2575
6. Moore, G. L., Chen, H., Karki, S., and Lazar, G. A. (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.. MAbs 2, 181-189
7. Natsume, A., Shimizu-Yokoyama, Y., Satoh, M., Shitara, K., and Niwa, R. (2009) Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.. Cancer Sci. 100, 2411-2418
8. Brezski, R. J., Vafa, O., Petrone, D., Tam, S. H., Powers, G., Ryan, M. H., Luongo, J. L., Oberholtzer, A., Knight, D. M., and Jordan, R. E. (2009) Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge.. Proc. Natl. Acad. Sci. U. S. A. 106, 17864-17869
9. Burton, D. R., Jefferis, R., Partridge, L. J., and Woof, J. M. (1988) Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI). Mol. Immunol. 25, 1175-1181
10. H2 domain and is modulated by the hinge region. J. Exp. Med. 173, 1483-1491
11. Duncan, A. R., and Winter, G. (1988) The binding site for C1q on IgG. Nature 332, 738-740
12. Duncan, A. R., Woof, J. M., Partridge, L. J., Burton, D. R., and Winter, G. (1988) Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332, 563-564
13. Hezareh, M., Hessell, A. J., Jensen, R. C., Van De Winkel, J. G., and Parren, P. W. (2001) Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75, 12161-12168
14. Hulett, M. D., Witort, E., Brinkworth, R. I., McKenzie, I. F., and Hogarth, P. M. (1994) Identification of the IgG binding site of the human low affinity receptor for IgG FcγRII. Enhancement and ablation of binding by sitedirected mutagenesis. J. Biol. Chem. 269, 15287-15293
15. Jefferis, R., Lund, J., and Pound, J. (1990) Molecular definition of interaction sites on human IgG for Fc receptors (huFcγR). Mol. Immunol. 27, 1237-1240
16. Lund, J., Winter, G., Jones, P. T., Pound, J. D., Tanaka, T., Walker, M. R., Artymiuk, P. J., Arata, Y., Burton, D. R., and Jefferis, R. (1991) Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG. J. Immunol. 147, 2657-2662
17. Partridge, L. J., Woof, J. M., Jefferis, R., and Burton, D. R. (1986) The use of anti-IgG monoclonal antibodies in mapping the monocyte receptor site on IgG. Mol. Immunol. 23, 1365-1372
18. Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J. A., and Presta, L. G. (2001) High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591-6604
19. Tamm, A., Kister, A., Nolte, K. U., Gessner, J. E., and Schmidt, R. E. (1996) The IgG binding site of human FcγRIIIB receptor involves CC' and FG loops of the membrane-proximal domain. J. Biol. Chem. 271, 3659-3666
20. Wines, B. D., Powell, M. S., Parren, P. W., Barnes, N., and Hogarth, P. M. (2000) The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors FcγRI and FcγRIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.. J. Immunol. 164, 5313-5318
21. Woof, J. M., Partridge, L. J., Jefferis, R., and Burton, D. R. (1986) Localisation of the monocyte-binding region on human immunoglobulin G. Mol. Immunol. 23, 319-330
22. Gearing, A. J., Thorpe, S. J., Miller, K., Mangan, M., Varley, P. G., Dudgeon, T., Ward, G., Turner, C., and Thorpe, R. (2002) Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol. Lett. 81, 41-48
23. Ryan, M. H., Petrone, D., Nemeth, J. F., Barnathan, E., Björck, L., and Jordan, R. E. (2008) Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid.. Mol. Immunol. 45, 1837-1846
24. Von Pawel-Rammingen, U., Johansson, B. P., and Björck, L. (2002) IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21, 1607-1615
25. Vincents, B., Von Pawel-Rammingen, U., Björck, L., and Abrahamson, M. (2004) Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding.. Biochemistry 43, 15540-15549
26. Fan, X., Brezski, R. J., Fa, M., Deng, H, Oberholtzer, A., Gonzalez, A., Dubinsky, W. P., Strohl, W. R., Jordan, R. E., Zhang, N., and An, Z. (2012) A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.. Breast Cancer Res. 14, R116
27. Brezski, R. J., and Jordan, R. E. (2010) Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs 2, 212-220
28. Von Pawel-Rammingen, U. (2012) Streptococcal IdeS and its impact on immune response and inflammation. J. Innate Immun. 4, 132-140
29. Brezski, R. J., Oberholtzer, A., Strake, B., and Jordan, R. E. (2011) The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.. MAbs 3, 558-567
30. Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., and Daëron, M. (2009) Specificity and affinity of human Fc7 receptors and their polymorphic variants for human IgG subclasses.. Blood 113, 3716-3725
31. Jefferis, R. (2007) Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7, 1401-1413
32. Armour, K. L., Clark, M. R., Hadley, A. G., and Williamson, L. M. (1999) Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities.. Eur. J. Immunol. 29, 2613-2624
33. Strohl, W. R., and Strohl, L. M. (2012) Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry, Woodhead Publishing, Cambridge, Uk
34. Natsume, A., Niwa, R., and Satoh, M. (2009) Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. DrugDes. Devel. Ther. 3, 7-16
35. Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C, Chung, H. S., Eivazi, A., Yoder, S. C, Vielmetter, J., Carmichael, D. F., Hayes, R. J., and Dahiyat, B. I. (2006) Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 103, 4005-4010
36. Stavenhagen, J. B., Gorlatov, S., Tuaillon, N, Rankin, C. T., Li, H., Burke, S., Huang, L., Vijh, S., Johnson, S., Bonvini, E., and Koenig, S. (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors.. Cancer Res. 67, 8882-8890
37. Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J. E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.. Nat Biotechnol. 17, 176-180
38. Dall Acqua, W. F., Cook, K. E., Damschroder, M. M., Woods, R. M., and Wu, H. (2006) Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177, 1129-1138
39. Yan, B., Boyd, D., Kaschak, T., Tsukuda, J., Shen, A., Lin, Y., Chung, S., Gupta, P., Kamath, A., Wong, A., Vernes, J. M., Meng, G. Y., Totpal, K., Schaefer, G., Jiang, G., Nogal, B., Emery, C, Vanderlaan, M., Carter, P., Harris, R., and Amanullah, A. (2012) Engineering upper hinge improves stability and effector function of a human IgG1. J. Biol. Chem. 287, 5891-5897
40. Grugan, K. D., McCabe, F. L., Kinder, M., Greenplate, A. R., Harman, B. C, Ekert, J. E., Van Rooijen, N, Anderson, G. M., Nemeth, J. A., Strohl, W. R., Jordan, R. E., and Brezski, R. J. (2012) Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J. Immunol. 189, 5457-5466
41. Ngo, C. V., Picha, K., McCabe, F., Millar, H., Tawadros, R., Tam, S. H., Nakada, M. T., and Anderson, G. M. (2007) CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models.. Int. J. Cancer 120, 1261-1267
42. Brezski, R. J., Luongo, J. L., Petrone, D., Ryan, M. H., Zhong, D., Tam, S. H., Schmidt, A. P., Kruszynski, M., Whitaker, B. P., Knight, D. M., and Jordan, R. E. (2008) Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs.. J. Immunol. 181, 3183-3192
43. Ang, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R., Hammond, E. H., Fu, K. K., and Milas, L. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.. Cancer Res. 62, 7350-7356
44. Johansson, N, Airola, K., Grénman, R., Kariniemi, A. L., Saarialho-kere, U., and Kähäri, V. M. (1997) Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.. Am. J. Pathol. 151, 499-508
45. Edelman, G. M., Cunningham, B. A., Gall, W. E., Gottlieb, P. D., Rutishauser, U., and Waxdal, M. J. (1969) The covalent structure of an entire γG immunoglobulin molecule. Proc. Natl. Acad. Sci. U. S. A. 63, 78-85
46. Nesspor, T. C, Raju, T. S., Chin, C. N, Vafa, O., and Brezski, R. J. (2012) Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1. J. Mol. Recognit. 25, 147-154
47. Oflazoglu, E., Stone, I. J., Brown, L., Gordon, K. A., Van Rooijen, N, Jonas, M., Law, C. L., Grewal, I. S., and Gerber, H. P. (2009) Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.. Br J. Cancer 100, 113-117
48. Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., and Desjarlais, J. R. (2008) Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7, 2517-2527
49. Roopenian, D. C, and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725
50. Mosser, D. M., and Edwards, J. P. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969
51. Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., and Niwa, R. (2008) Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68, 3863-3872
52. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C, Leonard, J. E., Raab, R., Newman, R. A., Hanna, N, and Anderson, D. R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445
53. Anderson, D. R., Grillo-López, A., Varns, C, Chambers, K. S., and Hanna, N. (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.. Biochem. Soc. Trans. 25, 705-708
54. Teeling, J. L., Mackus, W. J., Wiegman, L. J., Van Den Brakel, J. H., Beers, S. A., French, R. R., Van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., Parren, P. W., Glennie, M. J., and Van De Winkel, J. G. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177, 362-371
55. Kessenbrock, K., Plaks, V., and Werb, Z. (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67
56. Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., and Weiner, L. M. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.. Cancer Res. 61, 4750-4755
57. Cooper, J. B., and Cohen, E. E. (2009) Mechanisms of resistance to EGFR inhibitors in head and neck cancer. HeadNeck 31, 1086-1094
58. Tao, M.-H., and Morrison, S. L. (1989) Studies of aglycosylated chimeric mouse-human IgG Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.. J. Immunol. 143, 2595-2601
59. Sazinsky, S. L., Ott, R. G., Silver, N. W., Tidor, B., Ravetch, J. V., and Wittrup, K. D. (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. U. S. A. 105, 20167-20172
60. Jung, S. T., Reddy, S. T., Kang, T. H., Borrok, M. J., Sandlie, I., Tucker, P. W., and Georgiou, G. (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells.. Proc. Natl. Acad. Sci. U. S. A. 107, 604-609
61. Oganesyan, V., Damschroder, M. M., Leach, W., Wu, H., and Dall Acqua, W. F. (2008) Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol. Immunol. 45, 1872-1882
62. Johansson, B. P., Shannon, O., and Björck, L. (2008) IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One 3, e1692
63. Nandakumar, K. S., Johansson, B. P., Björck, L., and Holmdahl, R. (2007) Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum 56, 3253-3260
64. Nandakumar, K. S., and Holmdahl, R. (2008) Therapeutic cleavage of IgG: new avenues for treating inflammation. Trends Immunol. 29, 173-178
65. Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., and Tsien, R. Y. (2004) Tumor imaging by means of proteolytic activation of cellpenetrating peptides. Proc. Natl. Acad. Sci. U. S. A. 101, 17867-17872
66. Guentsch, A., Hirsch, C, Pfister, W., Vincents, B., Abrahamson, M., Sroka, A., Potempa, J., and Eick, S. (2013) Cleavage of IgG1 in gingival crevicular fluid is associated with the presence of Porphyromonas gingivalis.. J. Periodontal Res. 48, 458-465
67. Jefferis, R., Weston, P. D., Stanworth, D. R., and Clamp, J. R. (1968) Relationship between the papain sensitivity of human γG immunoglobulins and their heavy chain subclass.. Nature 219, 646-649
68. Turner, M. W., Bennich, H. H., and Natvig, J. B. (1970) Pepsin digestion of human G-myeloma proteins of different subclasses. I. The characteristic features of pepsin cleavage as a function of time. Clin. Exp. Immunol. 7, 603-625
69. Yee, A. M., Phan, H. M., Zuniga, R., Salmon, J. E., and Musher, D. M. (2000) Association between Fc7RIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30, 25-28
70. Sanders, L. A., Feldman, R. G., Voorhorst-Ogink, M. M., De Haas, M., Rijkers, G. T., Capel, P. J., Zegers, B. J., and Van De Winkel, J. G. (1995) Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils.. Infect. Immun. 63, 73-81
71. Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., Sabourin, J. C, and Boissière-Michot, F. (2009) Impact of FcγRIIa-FcγRIIIa polymorphisms and kRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.. J. Clin. Oncol. 27, 1122-1129
72. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., and Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc7RIIIa gene.. Blood 99, 754-758
73. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., Neri, T. M., and Ardizzoni, A. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.. J. Clin. Oncol. 26, 1789-1796
74. Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., and Shitara, K. (2004) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcγRIIIa functional polymorphism.. Clin. Cancer Res. 10, 6248-6255
75. Cragg, M. S., Morgan, S. M., Chan, H. T., Morgan, B. P., Filatov, A. V., Johnson, P. W., French, R. R., and Glennie, M. J. (2003) Complementmediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101, 1045-1052
76. Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., and Golay, J. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171, 1581-1587
77. Golay, J., Cittera, E., Di Gaetano, N., Manganini, M., Mosca, M., Nebuloni, M., Van Rooijen, N., Vago, L., and Introna, M. (2006) The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.. Haematologica 91, 176-183
78. Beers, S. A., Chan, C. H., James, S., French, R. R., Attfield, K. E., Brennan, C. M., Ahuja, A., Shlomchik, M. J., Cragg, M. S., and Glennie, M. J. (2008) Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.. Blood 112, 4170-4177
79. Beers, S. A., French, R. R., Chan, H. T., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., Kerr, J. P., Johnston, D. A., Johnson, P. W., Verbeek, J. S., Glennie, M. J., and Cragg, M. S. (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.. Blood 115, 5191-5201
80. Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., Wu, Y., Meng, Y. G., Gribling, P., Lin, Z., Nguyen, K., Tran, T., Zhang, Y., Rosen, H., Martin, F., and Chan, A. C. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817-826